Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Clonal Dynamics of Leukemic and Clonal Hematopoiesis Mutations Predict Relapse in Single Cell MRD Analysis of AML in First Complete Remission

Blood (2024) 144 (Supplement 1): 4337.

https://doi.org/10.1182/blood-2024-209953

Published: 2024

Journal Articles

Double-Blind, Placebo Controlled, Randomized, Multicenter, Phase II Study to Assess the Efficacy of the High Affinity CXCR4 Inhibitor BL-8040 As Addition to Consolidation Therapy in AML By the SAL and OSHO Leukemia Study Groups

Sonia Jaramillo Segura, Maxi Wass, Judith Schaffrath, Kathrin Rieger, Axel Nogai, Mathias Haenel, Regina Herbst, Friedrich Stoelzel, Christoph Röllig, Edgar Jost, Richard F. Schlenk, Richard Noppeney, Christian H. Brandts, Utz Krug, Katharina S. Goetze, Sebastian Buske, Axel Florschütz, Jörg Schubert, Bernhard Opitz, Martin Mohren, Eva Eßeling, Stephan von Witzendorff, Marion Subklewe, Martin Kaufmann, Norbert Frickhofen, Christian W Scholz, Kerstin Schäfer-Eckart, Volker Kunzmann, Martin Schmidt-Hieber, Herbert G. Sayer, Andreas Rank, Philipp Hemmati, Frank Schueler, Simone Kowoll, Marina Scheller, Jörg Steighardt, Bayram Edemir, Lutz Peter Mueller, Irit Gliko-Kabir, Beatrice Ludwig-Kraus, Sabine Edemir, Ella Sorani, Mascha Binder, Abi Vainstein, Shaul Kadosh, Cora Gromann, Andreas Wienke, Claudia D. Baldus, Uwe Platzbecker, Hubert Serve, Martin Bornhaeuser, Christian Junghanss, Carsten Mueller-Tidow

Blood (2022) 140 (Supplement 1): 3338–3340.

https://doi.org/10.1182/blood-2022-166748

Published: 2022

Journal Articles

A Phase I Safety and Feasibility Study to Evaluate Motixafortide (CXCR4/SDF-1 Inhibition) and Natalizumab (VLA-4/VCAM-1 Inhibition) As a Novel Regimen to Mobilize CD34+ Hematopoietic Stem Cells for Gene Therapy in Sickle Cell Disease

Zachary D. Crees, Michael P. Rettig, Reyka G. Jayasinghe, Peter Ruminski, Abi Vainstein, Ella Sorani, Allison A. King, John F. DiPersio

Blood (2022) 140 (Supplement 1): 10432–10433.

https://doi.org/10.1182/blood-2022-165454

Published: 2022

Journal Articles

Immunophenotypic and Single-Cell Transcriptional Profiling of CD34+ Hematopoietic Stem and Progenitor Cells Mobilized with Motixafortide (BL-8040) and G-CSF Versus Plerixafor and G-CSF Versus Placebo and G-CSF: A Correlative Study of the Genesis Trial

Zachary D. Crees, Michael Retting, Reyka G Jayasinghe, Keith E. Stockerl-Goldstein, Abi Vainstein, Ella Sorani, Debby Ickowicz, Liron Shemesh-Darvish, Shaul Kadosh, John F. DiPersio

Blood (2021) 138 (Supplement 1): 3816.

https://doi.org/10.1182/blood-2021-144297

Published: 2021

Journal Articles

Motixafortide (BL-8040) and G-CSF Versus Placebo and G-CSF to Mobilize Hematopoietic Stem Cells for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma: The Genesis Trial

Blood (2021) 138 (Supplement 1): 475.

https://doi.org/10.1182/blood-2021-144296

Published: 2021

Journal Articles

Hematopoietic Cell Transplantation of Higher CD34+ Cell Doses and Specific CD34+ Subsets Mobilized with Motixafortide and/or G-CSF Is Associated with Rapid Engraftment - a Post-Hoc Analysis of the Genesis Trial

Blood (2021) 138 (Supplement 1): 2849.

https://doi.org/10.1182/blood-2021-146783

Published: 2021

Journal Articles

The High Affinity CXCR4 Inhibitor, BL-8040, Impairs the Infiltration, Migration, Viability, and Differentiation of Regulatory T Cells

Michal Abraham, Inbal Mishalian, Abi Vainstein, Liron Shemesh-Darvish, Ella Sorani, Orly Eizenberg, Amnon Peled

Blood (2021) 138 (Supplement 1): 2804.

https://doi.org/10.1182/blood-2021-147142

Published: 2021

Journal Articles

Combined Inhibition of CXCR4 Signaling and System x c - Transporter Activity Induces Synthetic Lethality in T-ALL Cells By Suppressing Gsh and Inducing Ferroptosis

Jun Xia, PhD, Stephanie Sun, Matthew RM Jotte, Geoffrey L Uy, MD, Ella Sorani, PhD, Abi Vainstein, Liron Shemesh Davish, Katherine E Caldwell, William G Hawkins, Daniel C. Link, MD

Blood (2020) 136 (Supplement 1): 37.

https://doi.org/10.1182/blood-2020-142735

Published: 2020

Journal Articles

CXCR4 Inhibition with BL-8040 in Combination with Nelarabine in Patients with Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia / Lymphoblastic Lymphoma

Geoffrey L. Uy, MD, Tapan M. Kadia, MD, Wendy Stock, MD, Jonathan E Brammer, MD, Osnat Bohana-Kashtan, PhD, Abi Vainstein, Ella Sorani, PhD, Hemda Chen, PharmD, John F. DiPersio, MD PhD, Daniel C. Link, MD

Blood (2019) 134 (Supplement_1): 2630.

https://doi.org/10.1182/blood-2019-127121

Published: 2019

Journal Articles

CXCR4 Blockade By BL-8040 in T Cell Acute Lymphoblastic Leukemia Decreases Mitochondrial Mass and Induces Non-Apoptotic Cell Death

Jun Xia, PhD, Stephanie Sun, Matthew RM Jotte, Geoffrey L. Uy, MD, Osnat Bohana-Kashtan, PhD, Ella Sorani, PhD, Abi Vainstein, Amnon Peled, PhD, Daniel C. Link, MD

Blood (2019) 134 (Supplement_1): 2745.

https://doi.org/10.1182/blood-2019-128881

Published: 2019

Journal Articles

The CXCR4 Antagonist, BL8040, Is Highly Active Against Human T-ALL in Preclinical Models

Jun Xia, PhD, Matthew RM Jotte, Stephanie Sun, Geoffrey L. Uy, MD, Abi Vainstein, Ella Sorani, PhD, Osnat Bohana-Kashtan, PhD, Stephen Shaw, PhD, Daniel C. Link, MD

Blood (2018) 132 (Supplement 1): 2700.

https://doi.org/10.1182/blood-2018-99-117213

Published: 2018

Journal Articles

Phase II Study Evaluating the Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem and Progenitor Cells for Allogeneic Hematopoietic Cell Transplantation and Phenotypic Characterization of the Leukapheresis Product

Michael P. Rettig, PhD, Geoffrey L. Uy, MD, Asad Bashey, MD PhD, Steven Devine, Samantha Jaglowski, MDMPH, Abi Vainstein, MD, Ella Sorani, PhD, Hemda Chen, PharmD, Osnat Bohana-Kashtan, PhD, Stephen Shaw, PhD, Peter Westervelt, MDPhD, John F. DiPersio, MD PhD

Blood (2018) 132 (Supplement 1): 118.

https://doi.org/10.1182/blood-2018-99-109701

Published: 2018

Journal Articles

The CXCR4 Antagonist BL-8040 Induces a Robust Mobilization of CD34+CD38−CD45RA−CD90+ CD49f+ HSCs with Long-Term and Secondary Myeloid and Lymphoid Repopulating Activity

Michal Abraham, PhD, Galia Oberkovitz, PhD, Baruch Bulvik, Klein Shiri, Hanna Wald, Orly Eizenberg, Katia Beider, Arnon Nagler, MD, Abi Vainstein, MD, Eyal Benami, Rotem Golan, Eithan Galun, Yoseph Caraco, Reuven Or, MD, Amnon Peled

Blood (2017) 130 (Supplement 1): 660.

https://doi.org/10.1182/blood.V130.Suppl_1.660.660

Published: 2017

Journal Articles

The Selective Anti Leukemic Effect of BL-8040, a Peptidic CXCR4 Antagonist, Is Mediated By Induction of Leukemic Blast Mobilization, Differentiation and Apoptosis: Results of Correlative Studies from a Ph2a Trial in Acute Myeloid Leukemia

Blood (2016) 128 (22): 2745.

https://doi.org/10.1182/blood.V128.22.2745.2745

Published: 2016

Journal Articles

The Peptidic CXCR4 Antagonist, BL-8040, Significantly Reduces Bone Marrow Immature Leukemia Progenitors By Inducing Differentiation, Apoptosis and Mobilization: Results of the Dose Escalation Clinical Trial in Acute Myeloid Leukemia

Blood (2015) 126 (23): 2546.

https://doi.org/10.1182/blood.V126.23.2546.2546

Published: 2015

NARROW

Clonal Dynamics of Leukemic and Clonal Hematopoiesis Mutations Predict Relapse in Single Cell MRD Analysis of AML in First Complete Remission

Double-Blind, Placebo Controlled, Randomized, Multicenter, Phase II Study to Assess the Efficacy of the High Affinity CXCR4 Inhibitor BL-8040 As Addition to Consolidation Therapy in AML By the SAL and OSHO Leukemia Study Groups

A Phase I Safety and Feasibility Study to Evaluate Motixafortide (CXCR4/SDF-1 Inhibition) and Natalizumab (VLA-4/VCAM-1 Inhibition) As a Novel Regimen to Mobilize CD34+ Hematopoietic Stem Cells for Gene Therapy in Sickle Cell Disease

Immunophenotypic and Single-Cell Transcriptional Profiling of CD34+ Hematopoietic Stem and Progenitor Cells Mobilized with Motixafortide (BL-8040) and G-CSF Versus Plerixafor and G-CSF Versus Placebo and G-CSF: A Correlative Study of the Genesis Trial

Motixafortide (BL-8040) and G-CSF Versus Placebo and G-CSF to Mobilize Hematopoietic Stem Cells for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma: The Genesis Trial

Hematopoietic Cell Transplantation of Higher CD34+ Cell Doses and Specific CD34+ Subsets Mobilized with Motixafortide and/or G-CSF Is Associated with Rapid Engraftment - a Post-Hoc Analysis of the Genesis Trial

The High Affinity CXCR4 Inhibitor, BL-8040, Impairs the Infiltration, Migration, Viability, and Differentiation of Regulatory T Cells

Combined Inhibition of CXCR4 Signaling and System x c - Transporter Activity Induces Synthetic Lethality in T-ALL Cells By Suppressing Gsh and Inducing Ferroptosis

CXCR4 Inhibition with BL-8040 in Combination with Nelarabine in Patients with Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia / Lymphoblastic Lymphoma

CXCR4 Blockade By BL-8040 in T Cell Acute Lymphoblastic Leukemia Decreases Mitochondrial Mass and Induces Non-Apoptotic Cell Death

The CXCR4 Antagonist, BL8040, Is Highly Active Against Human T-ALL in Preclinical Models

Phase II Study Evaluating the Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem and Progenitor Cells for Allogeneic Hematopoietic Cell Transplantation and Phenotypic Characterization of the Leukapheresis Product

The CXCR4 Antagonist BL-8040 Induces a Robust Mobilization of CD34+CD38−CD45RA−CD90+ CD49f+ HSCs with Long-Term and Secondary Myeloid and Lymphoid Repopulating Activity

The Selective Anti Leukemic Effect of BL-8040, a Peptidic CXCR4 Antagonist, Is Mediated By Induction of Leukemic Blast Mobilization, Differentiation and Apoptosis: Results of Correlative Studies from a Ph2a Trial in Acute Myeloid Leukemia

The Peptidic CXCR4 Antagonist, BL-8040, Significantly Reduces Bone Marrow Immature Leukemia Progenitors By Inducing Differentiation, Apoptosis and Mobilization: Results of the Dose Escalation Clinical Trial in Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only